These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33929876)

  • 21. If it's a target, it's a pan-cancer target: Tissue is not the issue.
    Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
    Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.
    Kummar S; Lassen UN
    Target Oncol; 2018 Oct; 13(5):545-556. PubMed ID: 30276762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
    Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
    Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic Pancreatic Cancer: ASCO Guideline Update.
    Sohal DPS; Kennedy EB; Cinar P; Conroy T; Copur MS; Crane CH; Garrido-Laguna I; Lau MW; Johnson T; Krishnamurthi S; Moravek C; O'Reilly EM; Philip PA; Pant S; Shah MA; Sahai V; Uronis HE; Zaidi N; Laheru D
    J Clin Oncol; 2020 Sep; 38(27):3217-3230. PubMed ID: 32755482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies.
    Meti N; Kelly D; Allen MJ; Lanys A; Fazelzad R; Ramjeesingh R; Zogopoulos G; Notta F; Knox JJ; Amir E; Gallinger S; O'Kane G; Grant RC
    Cancer Treat Rev; 2021 Dec; 101():102310. PubMed ID: 34757307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular subtype specific efficacy of MEK inhibitors in pancreatic cancers.
    Brauswetter D; Gurbi B; Varga A; Várkondi E; Schwab R; Bánhegyi G; Fábián O; Kéri G; Vályi-Nagy I; Peták I
    PLoS One; 2017; 12(9):e0185687. PubMed ID: 28957417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Durable Response to Pembrolizumab in a Patient with Uterine Serous Carcinoma and Lynch Syndrome due to the MSH6 Germline Mutation.
    T Danley K; Schmitz K; Ghai R; Sclamberg JS; Buckingham LE; Burgess K; Kuzel TM; Usha L
    Oncologist; 2021 Oct; 26(10):811-817. PubMed ID: 34018286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
    Peters ML; Tseng JF; Miksad RA
    Clin Ther; 2016 Jul; 38(7):1622-35. PubMed ID: 27041411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquired multiple secondary
    Tao H; Liu S; Huang D; Han X; Wu X; Shao YW; Hu Y
    Am J Transl Res; 2020; 12(2):612-617. PubMed ID: 32194909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
    Sorscher S
    Oncologist; 2018 Nov; 23(11):1266-1268. PubMed ID: 29866945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PARP inhibition in treatment of pancreatic cancer.
    Hammel P; Zhang C; Matile J; Colle E; Hadj-Naceur I; Gagaille MP; Bouattour M; Cros J; de Mestier L; Lamuraglia M
    Expert Rev Anticancer Ther; 2020 Nov; 20(11):939-945. PubMed ID: 32936674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
    Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    Sahin IH; Lowery MA; Stadler ZK; Salo-Mullen E; Iacobuzio-Donahue CA; Kelsen DP; O'Reilly EM
    Expert Rev Gastroenterol Hepatol; 2016 Aug; 10(8):893-905. PubMed ID: 26881472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transforming approaches to treating TRK fusion cancer: historical comparison of larotrectinib and histology-specific therapies.
    Pollack M; Keating K; Wissinger E; Jackson L; Sarnes E; Cuffel B
    Curr Med Res Opin; 2021 Jan; 37(1):59-70. PubMed ID: 33148054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs.
    Han SY
    Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRK inhibitors in TRK fusion-positive cancers.
    Drilon A
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.